Detection of human papillomavirus and expression of osteopontin in cervical cancer specimens

Bao,Lidao; Si,Qin; Jia,Lizhou; Ren,Xianhua; Ma,Ruilian; Wang,Yi

doi:10.3892/mmr.2014.2647

Detection of human papillomavirus and expression of osteopontin in cervical cancer specimens

Authors:
- Lidao Bao
- Qin Si
- Lizhou Jia
- Xianhua Ren
- Ruilian Ma
- Yi Wang
View Affiliations

Affiliations: Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02120, USA, Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China
Published online on: October 15, 2014 https://doi.org/10.3892/mmr.2014.2647
Pages: 447-453

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To understand human papillomavirus (HPV) and expression of osteopontin (OPN) in cervical diseased tissues, HPV infection was detected in paraffin-embedded specimens of cervical lesions from 90 patients with cervical cancer. Three polymerase chain reaction (PCR) techniques were used to determine the detectable rate of HPV infection. Expression of HPV OPN protein was detected using immunohistochemical methods. When a pairwise comparison was made among the three PCR methods, χ2 analysis indicated P>0.05 for detection through the methods of MY09/11 and GP5+/6+, and P>0.05 through the methods of MY09/11 and Nested-PCR. This indicated that there was no statistically significant difference in the HPV infection detection sensitivity of these methods. However, χ2 comparison of the methods of GP5+/6+ and Nested-PCR indicated P<0.05, which demonstrated that there was a statistically significant difference. The rate of positive HPV DNA measured with Nested-PCR was significantly higher than that measured using the GP5+/6+ PCR method. The HPV OPN protein is expressed in cervical cancer, and the HPV OPN polypeptide antibody has broad spectrum reaction capacity and significant multivalence for HPV infection. Immunohistochemical detection was performed on tissue specimens using the purified rabbit HPV OPN polypeptide antibody. Sixty-one cases exhibited a positive result and 29 a negative result. The total rate of positive detection was 67.78%. HPV OPN may therefore serve as a candidate target for tumor treatment, including targeted therapies and vaccine development.

View Figures

View References

1	Luhn P and Wentzensen N: HPV-based tests for cervical cancer screening and management of cervical disease. Curr Obstet Gynecol Rep. 2:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
2	Regan JA and Laimins LA: Viral transformation of epithelial cells. Methods Mol Biol. 945:449–465. 2013. View Article : Google Scholar : PubMed/NCBI
3	Deberne M, Levy A, Mondini M, Dessen P, Vivet S, Supiramaniam A, Vozenin MC and Deutsch E: The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines’ in-vitro and in-vivo xenografts. Anticancer Drugs. 24:599–608. 2013.PubMed/NCBI
4	Srivastava S, Shahi UP, Dibya A, Gupta S and Roy JK: Distribution of HPV genotypes and involvement of risk factors in cervical lesions and invasive cervical cancer: a study in an Indian population. Int J Mol Cell Med. 3:61–73. 2014.PubMed/NCBI
5	Huh W, Williams E, Bramley T, Huang J and Poulios N: Cost-effectiveness of various combinations of human papillomavirus (hpv)-based testing, including genotyping for hpv 16/18, for cervical cancer screening. Value Health. 16:A142–A143. 2013. View Article : Google Scholar
6	Racey CS, Withrow DR and Gesink D: Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health. 104:159–166. 2013.PubMed/NCBI
7	Sadraeian M, Rasoul-Amini S, Mansoorkhani MJ, Mohkam M, Ghoshoon MB and Ghasemi Y: Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice. Int J Gynecol Cancer. 23:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
8	Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC and Kinney WK: Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 17(5 Suppl 1): s56–s63. 2013.PubMed/NCBI
9	Xu Q, Yuan B, Xue F, et al: OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark. 10:233–239. 2011.PubMed/NCBI
10	Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H and Pfister HJ: Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol. 86:1291–1296. 2005. View Article : Google Scholar : PubMed/NCBI
11	Herfs M, Parra-Herran C, Howitt BE, Laury AR, Nucci MR, Feldman S, et al: Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am J Surg Pathol. 37:1311–1318. 2013. View Article : Google Scholar
12	Wang S, Pang T, Gao M, Kang H, Ding W, Sun X, Zhao Y, Zhu W, Tang X, Yao Y and Hu X: HPV E6 induces eIF4E transcription to promote the proliferation and migration of cervical cancer. FEBS Lett. 587:690–697. 2013. View Article : Google Scholar : PubMed/NCBI
13	Branković I, Verdonk P and Klinge I: Applying a gender lens on human papillomavirus infection: cervical cancer screening, HPV DNA testing, and HPV vaccination. Int J Equity Health. 12:142013.PubMed/NCBI
14	Chang L, He X, Yu G and Wu Y: Effectiveness of HPV 16 viral load and the E2/E6 ratio for the prediction of cervical cancer risk among Chinese women. J Med Virol. 85:646–654. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chu A, Genden E, Posner M and Sikora A: A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician’s guide. Oncologist. 18:180–189. 2013.
16	Priebe AM: 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol. 56:44–50. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wentzensen N: Triage of HPV-positive women in cervical cancer screening. Lancet Oncol. 14:107–109. 2013. View Article : Google Scholar : PubMed/NCBI
18	Eide ML and Debaque H: HPV detection methods and genotyping techniques in screening for cervical cancer. Ann Pathol. 32:e15–e23. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, et al: HPV-associated lung cancers: an international pooled analysis. Carcinogenesis. 35:1267–1275. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xu Q, Xue F, Yuan B, Zhang L, Li J and He Z: The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population. Cancer Biomark. 11:147–153. 2012.PubMed/NCBI
21	Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr and Cuzick J; Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 208:184.e1–184.e11. 2013.PubMed/NCBI
22	Sasagawa T, Takagi H and Makinoda S: Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother. 18:807–815. 2012. View Article : Google Scholar : PubMed/NCBI
23	Pilch H, Günzel S, Schäffer U, Tanner B, Brockerhoff P, Maeurer M, et al: Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes - correlation with clinico-pathological parameters and prognostic significance. Zentralbl Gynakol. 123:91–101. 2001. View Article : Google Scholar
24	Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, Mackay H, Amir E and Liu G: p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 18:6407–6415. 2012. View Article : Google Scholar : PubMed/NCBI
25	Wang N, Yin D, Zhang S, Wei H, Wang S and Zhang Y, Lu Y, Dai S, Li W, Zhang Q and Zhang Y: TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population. PLoS One. 7:e452462012. View Article : Google Scholar : PubMed/NCBI
26	Wiwanitkit V: Prevalence of HPV genotypes in cervical cancer in Thailand. Int J Gynecol Cancer. 22:12902012. View Article : Google Scholar : PubMed/NCBI
27	Markman M: Risk of cervical cancer after HPV vaccination. Curr Pharm Des. 19:1488–1489. 2013.PubMed/NCBI
28	Fröberg M, Norman I, Johansson B, Hjerpe A, Weiderpass E and Andersson S: Liquid-based cytology with HPV triage of low-grade cytological abnormalities versus conventional cytology in cervical cancer screening. Curr Pharm Des. 19:1406–1411. 2013.PubMed/NCBI
29	Sharma M, Bruni L, Diaz M, Castellsagué X, de Sanjosé S, Bosch FX and Kim JJ: Using HPV prevalence to predict cervical cancer incidence. Int J Cancer. 132:1895–1900. 2013. View Article : Google Scholar : PubMed/NCBI
30	Szarewski A: HPV vaccination and cervical cancer. Curr Oncol Rep. 14:559–567. 2012. View Article : Google Scholar
31	Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D’Souza G, Watts DH, Levine AM, et al: Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA. 308:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
32	Huang CY, Chen JJ, Shen KY, Chang LS, Yeh YC, Chen IH, Chong P, Liu SJ and Leng CH: Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One. 7:e409702012. View Article : Google Scholar
33	Origoni M, Cristoforoni P, Costa S, Mariani L, Scirpa P, Lorincz A and Sideri M: HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice. Ecancermedicalscience. 6:2582012.PubMed/NCBI
34	Schmitz M, Driesch C, Jansen L, Runnebaum IB and Dürst M: Non-random integration of the HPV genome in cervical cancer. PLoS One. 7:e396322012. View Article : Google Scholar : PubMed/NCBI
35	Kaarthigeyan K: Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol. 33:7–12. 2012. View Article : Google Scholar : PubMed/NCBI
36	Barbisan G, Pérez LO, Contreras A and Golijow CD: TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol. 33:1549–1556. 2012.
37	Bosch FX, de Sanjosé S and Castellsagué X: The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial. Cancer Discov. 1:377–380. 2011. View Article : Google Scholar : PubMed/NCBI